The Safety and Efficacy of Specific TIL-TCM Cells for Advanced Relapse-refractory or Metastatic Pancreatic Cancer

NCT05438797 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

3

Enrollment

OTHER

Sponsor class

Conditions

Advanced Pancreatic Cancer

Interventions

DRUG: Adoptive TIL-TCM transfer therapy

Sponsor

Sizhen Wang

Collaborators

[object Object]